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Multicenter Study of Surveillance for Hospital-Onset Clostridium
difficile Infection by the Use of ICD-9-CM Diagnosis Codes
Erik R. Dubberke, MD; Anne M. Butler, MS; Deborah S. Yokoe, MD, MPH; Jeanmarie Mayer, MD;
Bala Hota, MD, MPH; Julie E. Mangino, MD; Yosef M. Khan, MD; Kyle J. Popovich, MD;
Kurt B. Stevenson, MD, MPH; L. Clifford McDonald, MD; Margaret A. Olsen, PhD, MPH;
Victoria J. Fraser, MD; for the Prevention Epicenters Program of the Centers for Disease Control and Prevention
objective. To compare incidence of hospital-onset Clostridium difficile infection (CDI) measured by the use of International Classification
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) discharge diagnosis codes with rates measured by the use of electronically
available C. difficile toxin assay results.
methods. Cases of hospital-onset CDI were identified at 5 US hospitals during the period from July 2000 through June 2006 with the
use of 2 surveillance definitions: positive toxin assay results (gold standard) and secondary ICD-9-CM discharge diagnosis codes for CDI.
The x2 test was used to compare incidence, linear regression models were used to analyze trends, and the test of equality was used to
compare slopes.
results. Of 8,670 cases of hospital-onset CDI, 38% were identified by the use of both toxin assay results and the ICD-9-CM code, 16%
by the use of toxin assay results alone, and 45% by the use of the ICD-9-CM code alone. Nearly half (47%) of cases of CDI identified by
the use of a secondary diagnosis code alone were community-onset CDI according to the results of the toxin assay. The rate of hospital-
onset CDI found by use of ICD-9-CM codes was significantly higher than the rate found by use of toxin assay results overall ( ),P ! .001
as well as individually at 3 of the 5 hospitals ( for all). The agreement between toxin assay results and the presence of a secondaryP ! .001
ICD-9-CM diagnosis code for CDI was moderate, with an overall k value of 0.509 and hospital-specific k values of 0.489–0.570. Overall,
the annual increase in CDI incidence was significantly greater for rates determined by the use of ICD-9-CM codes than for rates determined
by the use of toxin assay results ( ).Pp .006
conclusions. Although the ICD-9-CM code for CDI seems to be adequate for measuring the overall CDI burden, use of the ICD-9-
CM discharge diagnosis code for CDI, without present-on-admission code assignment, is not an acceptable surrogate for surveillance for
hospital-onset CDI.
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Clostridium difficile is the most commonly recognized cause
of infectious diarrhea in hospitalized patients. Several reports
suggest that the incidence and severity of C. difficile infection
(CDI) have been increasing in recent years, due in part to
transmission of a single, fluoroquinolone-resistant epidemic
strain with enhanced virulence characteristics.1-7 Given the
increase in the incidence and severity of CDI, a surveillance
system to track rates of CDI is necessary. In the absence of
a national surveillance system, International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
codes assigned at hospital discharge have been used as a sur-
rogate. Current national CDI rate estimates are based on a
national probability sample of patient discharge records from
nonfederal, short-stay hospitals.8 In early 2009, the US De-
partment of Health and Human Services identified the re-
duction of endemic CDI rates as a high-priority goal in their
Action Plan to Prevent Healthcare-Associated Infections and
proposed ICD-9-CM codes as a metric to measure CDI case
rates.9 Surveillance with administrative discharge data is ad-
vantageous, because the data are inexpensive to obtain and
readily available at all hospitals in the United States, thus
providing a nationally representative method for tracking CDI
rates.10,11 Conversely, case ascertainment by means of current
surveillance definitions (ie, symptoms of diarrhea or toxic
megacolon, combined with a positive result of a laboratory
assay and/or endoscopic or histopathologic evidence of pseu-
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domembranous colitis), the gold standard for CDI surveil-
lance, is labor intensive and expensive, because it requires
both microbiologic test results and medical record review.12
Data from 2 single-institution studies suggest that the ICD-
9-CM code for CDI may be an acceptable surrogate for track-
ing the overall CDI burden in the absence of toxin testing
results.13,14 However, no multicenter studies have been con-
ducted to evaluate CDI surveillance by means of ICD-9-CM
codes, nor have there been any studies reporting more than
1 year of data. There have not been any investigations of the
ability of ICD-9-CM codes to track rates of hospital-onset
CDI.
The objective of this study was to compare hospital-onset
CDI incidence rates measured by the use of ICD-9-CM dis-
charge diagnosis codes with CDI rates measured by the use
of electronically available C. difficile toxin assay results—the
gold standard—at multiple healthcare facilities during a 6-
year study period. We sought to determine the utility of ICD-
9-CM codes for overall hospital-onset CDI surveillance, as
well as for intrahospital and interhospital comparisons of
hospital-onset CDI incidence. In addition, we evaluated the
effect of surveillance with ICD-9-CM codes on the proportion
of cases of hospital-onset CDI relative to cases of community-
onset CDI and recurrent CDI.
methods
The study population included all adult patients admitted
and discharged during the period from July 1, 2000, through
June 30, 2006, at 5 hospitals participating in the Prevention
Epicenters Program of the Centers for Disease Control and
Prevention. These hospitals included Barnes-Jewish Hospital
(St Louis, Missouri), Brigham and Women’s Hospital (Bos-
ton, Massachusetts), the Ohio State University Medical Cen-
ter (Columbus, Ohio), Stroger Hospital of Cook County
(Chicago, Illinois), and University of Utah Hospital (Salt Lake
City, Utah). Eligibility was limited to patients aged at least
18 years. Approval for this study was obtained from the in-
stitutional review boards of the Centers for Disease Control
and Prevention and all participating centers.
Retrospective data were collected from hospital medical
informatics databases; the data included dates of hospital ad-
mission, discharge, and stool collection, as well as C. difficile
toxin assay results and the ICD-9-CM discharge diagnosis
code for CDI (008.45). Medical coders are trained to assign
this code to hospitalizations for which there is medical record
documentation by the treating clinician of gastroenteritis or
colitis due to C. difficile; positive laboratory test results alone
are not sufficient to warrant application of the code. This is
the only ICD-9-CM code specific for CDI.15
Case Definitions
Cases of hospital-onset CDI, defined as cases that occurred
for patients with nonrecurrent CDI that had onset more than
48 hours after admission, were identified by using 2 sur-
veillance definitions: positive toxin assay results and the sec-
ondary ICD-9-CM diagnosis code for CDI. Cases of CDI
identified from a positive toxin assay result were not consid-
ered to be hospital-onset CDI if the first positive toxin assay
result was for a sample obtained no more than 48 hours after
admission or if the patient had a positive toxin assay result
during the previous 8 weeks (which defined a case as recurrent
CDI). Because the presence of a primary ICD-9-CM code for
CDI suggests that CDI was the primary reason for hospital-
ization, cases identified by an ICD-9-CM code for CDI were
not considered to be hospital-onset CDI if the ICD-9-CM
diagnosis code was the primary discharge code. In addition,
since cases of CDI that occur in the same patient within 8
weeks after a previous case are considered recurrent, hospi-
talizations identified by an ICD-9-CM code for CDI were
considered recurrent if an ICD-9-CM code for CDI had been
assigned to a hospitalization for the same patient during the
previous 8 weeks.
Cases of community-onset CDI were defined as cases that
occurred for patients with nonrecurrent CDI and a positive
toxin assay result for a sample obtained no more than 48
hours after admission (by the toxin assay definition) or for
patients with a primary ICD-9-CM diagnosis code for CDI
(by the ICD-9-CM code definition). Cases of CDI were at-
tributed to the month of stool sample collection for the pos-
itive toxin assay result definition and to the month of dis-
charge from the hospital for the ICD-9-CM code definition.
For patients who had multiple positive toxin assay results
during a single hospitalization, only the first positive toxin
assay result was included in the analysis.
Statistical Analysis
Monthly CDI rates were calculated as the number of cases
per 1,000 patient discharges for each surveillance definition
(ie, positive C. difficile toxin assay result and ICD-9-CM
code). Patient discharges, rather than patient-days, were used
for the denominator because the date of CDI onset was not
known for cases of CDI indicated by ICD-9-CM code, and
the codes are assigned at discharge. Rates were compared with
the x2 test, with Bonferroni adjustment for multiple com-
parisons. Linear regression analysis was used to estimate the
annual change in CDI incidence, and the test of equality was
used to compare the slopes. The k statistic was calculated to
measure the agreement between C. difficile toxin assay results
and ICD-9-CM codes. Data from hospital D were incomplete
for the first 14 months and the last 14 months of the study
period; therefore, these months were excluded from the anal-
ysis for hospital D. All tests were 2-tailed, and a P value of
less than .05 was considered to indicate a significant differ-
ence. Statistical analyses were performed with Epi Info, ver-
sion 6 (Centers for Disease Control and Prevention), SPSS
for Windows, version 14.0 (SPSS), and Stata, version 9.2
(StataCorp).
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table 1. Method of Identifying Cases of Clostridium difficile In-




Positive 6,545 3,033 9,578
Negative 1,831 919,283 921,114
Total 8,376 922,316 930,692
note.—Data are no. of patient discharges.
figure 1. Identification of cases of hospital-onset Clostridium
difficile infection (CDI) identified with use of toxin assay results and/
or International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) codes, by hospital. The hospital-specific
k values were as follows: hospital A, 0.489; hospital B, 0.494; hospital
C, 0.570; hospital D, 0.499; and hospital E, 0.527. The overall k value
was 0.509.
results
The number of patient discharges from each hospital varied
(range, 84,984–318,847); a total of 930,692 patient discharges
occurred during the 6-year study period (Table 1). C. difficile
toxin assays had positive results for 8,376 (0.9%) of the dis-
charges, of which 3,435 (41%) cases were identified from
samples obtained within 48 hours after admission of the pa-
tient (ie, consistent with community-onset CDI) and 4,941
(59%) cases were identified from samples obtained more than
48 hours after admission (ie, consistent with hospital-onset
CDI). The ICD-9-CM code for CDI was assigned to 9,578
(1%) of the discharges, for which the primary diagnosis code
for CDI was present in the medical record for 1,339 (14%)
and the secondary diagnosis code for CDI was present for
8,239 (86%). Six hundred twenty-four (7%) cases of CDI
identified by means of toxin assays occurred for patients who
had a prior positive toxin assay result during the previous 8
weeks, and 1,237 (13%) cases of CDI identified by means of
the ICD-9-CM code for CDI occurred for patients who had
a CDI code assigned to a hospitalization during the previous
8 weeks. Compared with toxin assay results, the sensitivity
and specificity of ICD-9-CM codes for tracking the overall
CDI burden were 78.1% and 99.7%, respectively.
Of 8,670 cases of hospital-onset CDI identified during the
study period by use of a secondary ICD-9-CM diagnosis code
and/or toxin assay result, 3,335 cases (38%) were identified
by both toxin assay result and code, 1,419 cases (16%) were
identified by toxin assay result alone, and 3,916 cases (45%)
were identified by code alone (Figure 1). The use of secondary
diagnosis codes identified 53% more cases of hospital-onset
CDI than did the use of toxin assay results. The agreement
between toxin assay results and diagnosis codes was moderate;
the overall k value was 0.509, and hospital-specific k values
were 0.489–0.570. Compared with the toxin assay definition,
the diagnosis code definition classified a significantly higher
proportion of cases of CDI as hospital-onset CDI (76% vs
57%; ) rather than community-onset CDI or recur-P ! .001
rent CDI. Of the 3,916 discordant cases classified as hospital-
onset CDI by the secondary ICD-9-CM diagnosis code def-
inition but not by the toxin assay definition, the toxin assay
definition classified 1,828 (47%) as community-onset CDI,
84 (2%) as recurrent CDI, and 2,004 (51%) as not CDI (Fig-
ure 2).
Table 2 presents hospital-onset CDI rates according to sur-
veillance definition. Overall, the rates of hospital-onset CDI
were significantly higher with the use of ICD-9-CM codes
than with the use of toxin assays (7.8 vs 5.1 cases per 1,000
discharges; ). The rates of hospital-onset CDI for theP ! .001
entire study period found with the use of ICD-9-CM codes
were higher than the rates found with the use of toxin assay
results at all 5 hospitals, with significant differences at 3 of
5 hospitals ( for hospitals A, C, and E) and a mar-P ! .001
ginally significantly difference at a fourth hospital (Pp
for hospital D). Figures 3 and 4 present annual rates of.092
hospital-onset CDI according to surveillance definition, over-
all and stratified by hospital. Across hospitals, there was sig-
nificant variation in the number of additional cases of hos-
pital-onset CDI identified with the use of ICD-9-CM codes,
compared with the use of toxin assay results (test of equality,
). The use of the codes identified 6% more cases ofP ! .001
hospital-onset CDI than did the use of toxin assays at hospital
B, 14% more at hospital D, 36% more at hospital A, 129%
more at hospital C, and 142% more at hospital E.
The annual rates of hospital-onset CDI were also signifi-
cantly higher with the use of ICD-9-CM codes than with the
use of toxin assay results for the entire study population
( for each year) (Figure 3). Within hospitals, the num-P ! .001
ber of years during which there was a significant difference
in the incidence of hospital-onset CDI detected with different
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figure 2. Classification of cases of Clostridium difficile infection
(CDI) by use of the toxin assay result definition for the 3,916 dis-
cordant cases classified as hospital-onset C. difficile infection by the
International Classification of Diseases, Ninth Revision, Clinical Mod-
ification code definition alone.
table 2. Incidences of Hospital-Onset Clostridium difficile Infection (CDI) Identified by Surveillance with International





ICD-9-CM code Toxin assay result
PNo. of cases of CDI
No. of cases
of CDI per 1,000
discharges No. of cases of CDI
No. of cases
of CDI per 1,000
discharges
A 318,847 3,334 10.5 2,460 7.7 !.001
B 110,437 915 8.3 863 7.8 .219
C 254,073 1,253 4.9 548 2.2 !.001
D 84,984 345 4.1 302 3.6 .092
E 162,351 1,404 8.6 581 3.6 !.001
Total 930,692 7,251 7.8 4,754 5.1 !.001
surveillance definitions varied (range, 0–6 cases per 1,000
discharges) (Figure 4). Of the 28 annual time points in the
analysis (ie, 6 years for hospitals A, B, C, and E and 4 years
for Hospital D), half (14 time points) had rates of hospital-
onset CDI that differed significantly by surveillance defini-
tion, after correction for multiple comparisons ( forP ! .001
all). Hospitals C and E had significantly higher rates with the
use of ICD-9-CM codes than with the use of toxin assay
results for every year of the 6-year study period. Hospital A
had significantly higher rates with the use of the codes than
with the use of toxin assay results for the last 4 years of the
study period. At hospitals B and D, the rates of hospital-onset
CDI did not differ by surveillance definition for any year.
While the overall annual incidences of hospital-onset CDI
increased almost every year of the study period regardless of
the surveillance definition used, the annual increase in in-
cidence was significantly higher for the rates found with the
use of ICD-9-CM codes than for the rates found with the use
of toxin assay results (b, 0.908 vs 0.327; ; Figure 3).Pp .006
At 3 hospitals, the annual increase in CDI incidence was
higher for rates found with the use of ICD-9-CM codes than
for rates found with the use of toxin assay results (Figure 4),
with significant differences at hospital A (b, 0.990 vs 0.035;
) and hospital C (b, 0.583 vs 0.151; ) andPp .014 Pp .025
a nonsignificant difference at hospital E (b, 0.900 vs 0.447;
).Pp .129
discussion
The results of this multicenter study of patients admitted to
5 geographically diverse academic medical centers suggest that
ICD-9-CM codes may be an adequate surrogate for tracking
the overall CDI burden, but comparison with toxin assay
results reveals that ICD-9-CM codes are of little to no use
for tracking hospital-onset CDI incidence. Consistent with
previous reports, the sensitivity and specificity of ICD-9-CM
codes for tracking the overall CDI burden were 78.1% and
99.7%, respectively, compared with the use of toxin assay
results, which suggests that these codes are an adequate sur-
rogate for tracking CDI prevalence. However, ICD-9-CM
codes demonstrated only moderate agreement with toxin as-
say results for identification of cases of hospital-onset CDI.
Use of the codes significantly overreported the incidence of
hospital-onset CDI compared with use of toxin assay results,
and the degree to which hospital-onset CDI incidence was
overreported with use of the codes varied by year and by
hospital. In addition, the annual increase found in the in-
cidence of hospital-onset CDI was greater with the use of
ICD-9-CM codes than that found with the use of toxin assay
results overall and at 3 of the individual hospitals. These
results indicate that ICD-9-CM codes would not have been
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figure 3. Overall annual incidence of hospital-onset Clostridium
difficile infection (CDI) at the study hospitals, according to sur-
veillance definition. The annual increase in incidence was signifi-
cantly higher for the rates found with the use of International Clas-
sification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) codes than the rates found with the use of toxin assay results
(b, 0.908 vs 0.327; ).Pp .006
useful for overall hospital-onset CDI surveillance, nor would
they be useful for intrahospital or interhospital comparisons
of CDI incidence during the study period.
Previous studies of CDI surveillance with the use of ICD-
9-CM codes have focused on the overall CDI burden rather
than hospital-onset CDI. Data from 2 single-institution stud-
ies suggest that ICD-9-CM codes are an acceptable surrogate
for tracking the overall CDI burden in the absence of toxin
testing results.13,14 In a cohort of patients hospitalized in 2003
at Barnes-Jewish Hospital, there was good agreement between
ICD-9-CM codes and toxin assay results for CDI case ascer-
tainment ( ).13 In this study, ICD-9-CM codes had akp 0.72
sensitivity of 78.0% and a specificity of 99.7%. These results
were remarkably similar to those of a study by Scheurer and
colleagues14 of patients hospitalized in 2004 at Brigham and
Women’s Hospital. These investigators reported a sensitivity
of 71% and a specificity of 99% for CDI surveillance with
the use of ICD-9-CM codes, compared with the use of positive
toxin assay results. In the present study, the sensitivity
(78.1%) and specificity (99.7%) of ICD-9-CM codes for track-
ing the overall CDI burden were consistent with those of
previous reports. This suggests that ICD-9-CM codes may be
an adequate surrogate for tracking overall CDI prevalence,
compared with the use of toxin assay results. It is possible
that the disparity in the ability of ICD-9-CM codes to track
overall CDI compared with their ability to track hospital-
onset CDI can be explained by an inherent limitation of
surveillance based on ICD-9-CM codes: the codes are assigned
to the date of discharge rather than the date of diagnosis and
thus do not give any information regarding the date of CDI
onset. In our study, 47% of the cases of CDI discordantly
classified as hospital-onset CDI according to the ICD-9-CM
code definition but not according the toxin assay result def-
inition occurred for patients who had their first positive toxin
assay result for a sample obtained within 48 hours after ad-
mission and therefore were cases of community-onset CDI,
according to the gold standard definition. In the future, pre-
sent-on-admission codes, which became mandatory for the
records of Medicare patients discharged on or after October
1, 2007 (ie, after the study period), may add precision to CDI
surveillance based on ICD-9-CM codes by providing a mech-
anism to distinguish preexisting conditions, ultimately re-
ducing misclassification of cases of community-onset CDI.16
Medical record review was not performed for this study;
however, prior studies have used medical record review to
investigate discrepancies in CDI case ascertainment between
toxin assay and ICD-9-CM code surveillance definitions. In
our study, 3,916 (45%) cases of CDI were identified as hos-
pital-onset CDI by use of the ICD-9-CM code surveillance
definition but not by use of the toxin assay surveillance def-
inition. We found that 1,912 (49%) of these cases were mis-
classified as hospital-onset CDI according to the ICD-9-CM
codes, because according to the toxin assay results, they were
community-onset CDI (1,828 cases) or recurrent CDI (84
cases). There were no corresponding positive toxin assay re-
sults for the remaining 2,004 (51%) of these cases. Scheurer
et al14 performed medical record review for the 35 patients
with an ICD-9-CM code for CDI but without a positive toxin
assay result in their study and reported that all of these pa-
tients had a prior history of CDI documented in their medical
history but did not have active disease during the hospital
stay. In our previous study at Barnes-Jewish Hospital, 142
patients (59%) with an ICD-9-CM code for CDI but without
a positive toxin assay result had a past history of CDI.13 In
addition, 137 patients (57%) with an ICD-9-CM code but
without a positive toxin assay result had at least 1 order for
toxin testing, and 130 (95%) of these had at least 1 negative
toxin test result. It is possible that many of the patients in
this study identified as having hospital-onset CDI without a
corresponding toxin assay result had only a past history of
CDI. Alternatively, some of these cases could have occurred
among patients with diarrhea whose physicians noted a high
clinical suspicion of CDI but who never had a positive toxin
assay result.
In our current study, 16% of the cases of hospital-onset
CDI were identified using the toxin assay surveillance defi-
nition alone. This discrepancy may have occurred, in part,
because toxin assay results were pending at discharge. We
previously reported that hospitalizations of patients who had
only a positive toxin assay result and no ICD-9-CM code for
CDI were more likely than hospitalizations of patients with
concordant CDI classification to have their first positive toxin
assay result for a sample obtained within the 48 hours before
discharge (44% vs 14%; ).13 In our current study, theP ! .01
median duration between obtaining the first sample with a
positive toxin assay result and hospital discharge was signif-
icantly shorter for hospitalizations of patients with only a
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figure 4. Annual incidence of hospital-onset Clostridium difficile infection (CDI) at individual study hospitals, according to surveillance
definition. Asterisks indicate significantly higher annual incidences found with the use of International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes compared with rates found with the use of toxin assay results ( ).P ! .001
positive toxin assay result than for hospitalizations of patients
with concordant CDI classification (4 vs 9 days; Mann-Whit-
ney U test, ). The first stool sample positive for CDIP ! .001
was collected within 2 days before discharge for 541 (38%)
of 1,419 hospitalizations of patients with a positive toxin assay
result only, compared with 357 (11%) of 3,335 hospitaliza-
tions of patients with concordant CDI classification (P !
). For these hospitalizations, toxin assay results may not.001
yet have been known at the time of patient discharge and
therefore were not noted in the physician’s discharge sum-
mary for medical coders to capture.
There are several additional limitations to surveillance for
hospital-onset CDI based on ICD-9-CM codes. First, the ret-
rospective nature of administrative data causes a time lag in
code assignment, since ICD-9-CM codes are assigned after
patients are discharged from the hospital. Second, discharge
diagnosis codes reflect conditions diagnosed or treated during
the entire hospitalization but do not give information re-
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garding the hospital location or date of CDI onset. Therefore,
surveillance based on ICD-9-CM codes cannot be used for
ward-level surveillance. Last, CDI is currently slated for Phase
III of Centers for Medicare and Medicaid Services nonreim-
bursable diagnoses. This may affect the utility of ICD-9-CM
codes for conducting CDI surveillance, if the frequency of
hospital-onset CDI coding is altered.
This study was limited to academic medical centers located
in urban areas. Although medical coding practices are the-
oretically standardized across institutions, there may be dif-
ferences in coding practices according to hospital size, geo-
graphic location, or teaching status. In addition, there may
be differences in patient populations or physician practices
at urban, academic medical centers, compared with other
acute care settings, that influence the likelihood that a patient
has CDI diagnosed or is assigned the ICD-9-CM code for
CDI.
Despite these limitations, the utilization of ICD-9-CM
codes is potentially valuable for CDI surveillance because the
data are readily available from hospital billing databases and
provide a universal method of surveillance. The codes appear
to be adequate for measuring the overall CDI burden; how-
ever, our data from 2000 through 2006 indicate that ICD-9-
CM codes are not an adequate substitution for toxin assay
results for surveillance of hospital-onset CDI. The recent im-
plementation of present-on-admission code assignment offers
a potential mechanism to differentiate community-onset CDI
from hospital-onset CDI and ultimately to improve the ac-
curacy of surveillance based on ICD-9-CM codes. Additional
work is needed to evaluate the effect that present-on-admis-
sion codes have on hospital-onset CDI surveillance in mul-
tiple acute care settings before ICD-9-CM codes can be con-
sidered for hospital-onset CDI surveillance.
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